Cargando…

Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma

Multiple myeloma (MM) is a heterogeneous disease characterized by significant genomic instability. Recently, a causal role for the AID/APOBEC deaminases in inducing somatic mutations in myeloma has been reported. We have identified APOBEC/AID as a prominent mutational signature at diagnosis with fur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Talluri, Srikanth, Samur, Mehmet K., Buon, Leutz, Kumar, Subodh, Potluri, Lakshmi B., Shi, Jialan, Prabhala, Rao H., Shammas, Masood A., Munshi, Nikhil C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501035/ https://www.ncbi.nlm.nih.gov/pubmed/34625538 http://dx.doi.org/10.1038/s41408-021-00554-9

Ejemplares similares

RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid Tumors
por: Liao, Chengcheng, et al.
Publicado: (2022)

Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma
por: Kumar, Subodh, et al.
Publicado: (2021)

Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance
por: Kumar, Subodh, et al.
Publicado: (2018)

Impact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett’s Adenocarcinoma Cells
por: Pal, Jagannath, et al.
Publicado: (2017)

RAD51 Inhibitor Reverses Etoposide-Induced Genomic Toxicity and Instability in Esophageal Adenocarcinoma Cells
por: Liao, Chengcheng, et al.
Publicado: (2020)

Targeting homologous recombination and telomerase in Barrett’s adenocarcinoma: Impact on telomere maintenance, genomic instability, and tumor growth
por: Lu, Renquan, et al.
Publicado: (2013)

Deciphering the chronology of copy number alterations in Multiple Myeloma
por: Aktas Samur, Anil, et al.
Publicado: (2019)

In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
por: Aktas Samur, Anil, et al.
Publicado: (2022)

The roles of homologous recombination and the immune system in the genomic evolution of cancer
por: Nandi, B, et al.
Publicado: (2018)

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
por: Samur, Mehmet Kemal, et al.
Publicado: (2020)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2021)

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2023)

CCL20 induces colorectal cancer neoplastic epithelial cell proliferation, migration, and further CCL20 production through autocrine HGF-c-Met and MSP-MSPR signaling pathways
por: Nandi, Bisweswar, et al.
Publicado: (2021)

Long Intergenic Non-Coding RNAs have an Independent Impact on Survival in Multiple Myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2018)

A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients
por: Bae, Jooeun, et al.
Publicado: (2014)

The shaping and functional consequences of the dosage effect landscape in multiple myeloma
por: Samur, Mehmet K, et al.
Publicado: (2013)

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
por: Qasaimeh, Mohammad A., et al.
Publicado: (2017)

Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma
por: Prabhala, Rao H., et al.
Publicado: (2015)

Genomic patterns of progression in smoldering multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2018)

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines
por: Maura, F, et al.
Publicado: (2018)

Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma
por: Ray, Arghya, et al.
Publicado: (2022)

APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression
por: Yamazaki, Hiroyuki, et al.
Publicado: (2020)

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2021)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

CCR6, the Sole Receptor for the Chemokine CCL20, Promotes Spontaneous Intestinal Tumorigenesis
por: Nandi, Bisweswar, et al.
Publicado: (2014)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma
por: Ruiz-Heredia, Yanira, et al.
Publicado: (2021)

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma
por: Fulciniti, Mariateresa, et al.
Publicado: (2018)

Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma
por: Gullà, Annamaria, et al.
Publicado: (2017)

Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
por: Fernandez, Rafael Alonso, et al.
Publicado: (2022)

Nucleotide excision repair is a potential therapeutic target in multiple myeloma
por: Szalat, R, et al.
Publicado: (2018)

miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth
por: Fulciniti, M, et al.
Publicado: (2016)

Prognostic value, immune signature and molecular mechanisms of the APOBEC family members APOBEC1, APOBEC3A, APOBEC3G and APOBEC3H in pancreatic adenocarcinoma
por: Duan, Yunjie, et al.
Publicado: (2022)

Risk Assessment to Evaluate if Crayons Complying with the Consumer Product Safety Improvement Act of 2008 for Lead, Also Comply with California Proposition 65
por: Ahmad, Gulzar R., et al.
Publicado: (2017)

P831: NOVEL IMMUNOSUPPRESSIVE MYELOID POPULATIONS IN THE BONE MARROW (BM) AND OSTEOLYTIC LESIONS (OL) OF MULTIPLE MYELOMA (MM) PATIENTS
por: Hillengass, Jens, et al.
Publicado: (2023)

FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis
por: Waters, Catherine E., et al.
Publicado: (2014)

Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2022)

Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
por: Merz, Maximilian, et al.
Publicado: (2022)

canEvolve: A Web Portal for Integrative Oncogenomics
por: Samur, Mehmet Kemal, et al.
Publicado: (2013)

Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13
por: Song, Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dkaobubi9m53b9huavkb2ail0e